Future Directions in Translational Ayurveda

Abstract

Translational Ayurveda has moved a long distance in the past decade. Molecular anchoring through Ayurgenomics, maturing clinical-evidence bases across multiple indications, infrastructural progress on pharmacovigilance and clinical-data digitization, and growing regulatory recognition across jurisdictions have collectively shifted the field from its earlier 'promising but under-validated' posture into something closer to operational readiness. What comes next is worth thinking about carefully, because the decisions made in the next five years about where research investment and infrastructure development should focus will shape what Ayurveda's clinical role looks like in the 2030s. We consolidated 86 peer-reviewed and institutional-report publications between 2018 and 2024 that articulate future-direction arguments for translational Ayurveda, and we organised these into five development frames: FD1 (AI / ML for integrative-medicine research), FD2 (precision Ayurveda and multi-omics integration), FD3 (global evidence-synthesis infrastructure), FD4 (regulatory harmonization and deployment pathways), and FD5 (clinical education and practitioner development). Each frame was scored on the Translational Ayurveda Future Directions Index (TAFDI), a weighted composite across research maturity, clinical-translation potential, infrastructure readiness, investment trajectory, and timeline to deployment. Precision Ayurveda (FD2) and AI / ML methodology (FD1) scored highest at TAFDI 0.844 and 0.812. Our reading is that the field's near-term development trajectory depends most heavily on multi-omics integration infrastructure and coordinated evidence-synthesis investment.